SV2 Binding Assay for Botulinum Neurotoxin Inhibitor Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for botulinum intoxication, such as antitoxin derived from horses, suffer from high production costs, immune reactions, and require cold chain delivery, while small molecule inhibitors targeting the catalytic domain have limited therapeutic effects in vivo due to poor cell entry.
Innovation Solution
A method is developed to identify agents that reduce the binding of clostridial neurotoxins to synaptic vesicle glycoprotein 2 (SV2) using a fusion protein comprising the receptor binding domain of botulinum neurotoxin fused to a reporter protein, allowing high-throughput screening for inhibitors through a sensitive and specific assay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antitoxin therapy is used to neutralize botulinum toxin, then the toxic effects are neutralized, but severe side effects including anaphylactic shock occur due to foreign protein administration
Solution Approach 1:
The patent replaces expensive, fragile equine antitoxin with stable, inexpensive small molecule inhibitors that can be administered repeatedly. These small molecules target the catalytic domain of the toxin and do not provoke immune responses, eliminating the need for cold chain delivery and repeated horse vaccinations.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediaries that block the catalytic activity of botulinum toxin without requiring direct antibody-toxin binding. These molecules act as mediators that prevent toxin function through a different mechanism, avoiding the immune reactions associated with foreign protein administration.
2Reliability
If equine antitoxin is administered to neutralize botulinum toxin, then neutralization occurs, but the therapy is very expensive due to horse requirements and safety facility restrictions
Solution Approach 1:
The patent replaces expensive, fragile equine antitoxin with stable, inexpensive small molecule inhibitors that can be administered repeatedly. These small molecules target the catalytic domain of the toxin and do not provoke immune responses, eliminating the need for cold chain delivery and repeated horse vaccinations.
3Reliability
If equine antitoxin is used for therapy, then neutralization capacity is achieved, but cold chain delivery is required which limits distribution
Solution Approach 1:
The patent replaces expensive, fragile equine antitoxin with stable, inexpensive small molecule inhibitors that can be administered repeatedly. These small molecules target the catalytic domain of the toxin and do not provoke immune responses, eliminating the need for cold chain delivery and repeated horse vaccinations.
4Ease of manufacture
If small molecule inhibitors targeting catalytic domain are used, then production cost is reduced and immune reactions are avoided, but therapeutic effect in vivo is limited due to poor cell entry
Solution Approach 1:
The patent divides the botulinum toxin into functional domains (receptor binding domain HC and catalytic domain LC) and develops inhibitors that specifically target the catalytic domain. By segmenting the inhibition strategy, the patent can optimize each domain's function - using small molecules for catalytic inhibition while avoiding the need for these molecules to enter cells, thus resolving the cell entry problem.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the identification of compounds that effectively inhibit neurotoxin binding to SV2, demonstrating therapeutic potential in vivo and evaluating antitoxin preparations without the need for specialized safety measures.
Implementation Method 1
a first fusion protein, said first fusion protein comprising a receptor binding domain of botulinum neurotoxin (BoNT Hc fragment) fused to a reporter protein, with a second protein, said second protein comprising the fourth luminal loop of the synaptic vesicle glycoprotein 2 (SV2)
Data Source
AI summary
The presently claimed subject matter concerns methods and kits for identifying agents that reduce binding of a clostridial neurotoxin to synaptic vesicle glycoprotein 2 (SV2).